Skip to main content
Joyce O'Shaughnessy, MD, Oncology, Dallas, TX

JoyceAnnO'ShaughnessyMD

Oncology Dallas, TX

Physician

Dr. O'Shaughnessy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. O'Shaughnessy's full profile

Already have an account?

  • Office

    3410 Worth St
    Dallas, TX 75246
    Phone+1 214-370-1000
    Fax+1 214-370-1809

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1982 - 1985
  • Yale School of Medicine
    Yale School of MedicineClass of 1982

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1997 - 2026
  • IN State Medical License
    IN State Medical License 1995 - 1999
  • KY State Medical License
    KY State Medical License 1995 - 1999
  • MD State Medical License
    MD State Medical License 1985 - 1995
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone... 
    2019 ASCO Annual Meeting - 6/1/2019
  • First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 lo... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or ... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • What Is Inflammatory Breast Cancer? Patient Jennifer Cordts Talks with Dr. Joyce O’Shaughnessy
    What Is Inflammatory Breast Cancer? Patient Jennifer Cordts Talks with Dr. Joyce O’ShaughnessyFebruary 28th, 2023
  • Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCS
    Anti-CDK4/6 in Metastatic Breast Cancer Showed Further Benefits at SABCSJanuary 24th, 2023
  • Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast Cancer
    Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast CancerOctober 20th, 2021
  • Join now to see all